ETFs: Drug Pricing Policy Shapes PPH Risks in 2026
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Pharma
This Pharma tag page compiles 4 recent articles on Moderna, Lilly, ANIP, and pharma dividends to help you spot opportunities and manage risk in your portfolio.
10 articlesLilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Lilly Just Opened Door to a GLP-1 Growth Boom in Markets
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...
Merck Price Prediction: Sac-TMT Could Lift MRK to Peak
Analysts are arguing that Merck's sac-TMT program could unlock substantial upside for MRK, supported by a strong pipe...
Hims Hers Really Growth Stock Faces Reality Check Now
Hims & Hers Health shifts to selling branded Wegovy and Ozempic after a settlement with Novo Nordisk, reversing regul...
Is It Still Worth Buying GSK After a 46% Rally in Shares This Year
GSK has seen a steep run in its stock, prompting questions about whether the rally still offers upside. This article ...
How a Pharma Dividend Stock Could Grow Your Retirement
A strong pharma dividend stock could be a powerful component of a retirement plan. Learn how to choose, invest, and c...
Pharma (ANIP) 2025 Earnings: ANIP Financial Outlook
ANI Pharma's Q4 2025 results set the stage for the pharma space. This guide breaks down what the numbers mean for the...
Lilly Just Took Major Steps Forward in Obesity Drug Market
Two bold moves by Eli Lilly are reshaping the billion-dollar obesity drug market. This guide breaks down what happene...
Moderna Stock Just Popped: What Investors Need to Know
A regulatory hint sent Moderna stock just popped, but the journey from acceptance to approval matters. This guide bre...